A retrospective population–based (49) cohort study of T2D (N = 216,816) revealed that DPP4 inhibitor usage was not associated with change in fracture risk compared to controls and other non-insulin anti-diabetic drug usage. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.